Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline. Review uri icon

Overview

abstract

  • On 27 August, 2018, the US Food and Drug Administration approved eravacycline, a fluorocycline antimicrobial agent within the tetracycline class of antibacterial drugs, for the treatment of complicated intra-abdominal infections in patients aged 18 years and older. This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work. This paper examines the in-vivo pharmacokinetic/pharmacodynamic work that led to the approval of eravacycline and explores how this important new antibiotic may be used to treat aggressive multidrug-resistant infections in the years ahead.

publication date

  • September 1, 2019

Research

keywords

  • Anti-Bacterial Agents
  • Intraabdominal Infections
  • Tetracyclines

Identity

Scopus Document Identifier

  • 85065305010

Digital Object Identifier (DOI)

  • 10.1007/s40262-019-00767-z

PubMed ID

  • 31049869

Additional Document Info

volume

  • 58

issue

  • 9